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Abstract The bcl-2 protein suppresses apoptosis and the bax 
protein opposes the cytoprotective ffect of bcl-2. A decrease in 
bcl-2 levels has been implicated in the induction of apoptosis 
during the terminal differentiation of HL60 myeloid leukaemia 
cells. We show here that bax protein also declined with a time 
course similar to the downregulation of bcl-2 following treatment 
of HL60 with phorbol myristate acetate (PMA), dimethyl 
sulphoxide (DMSO) or retinoic acid (RA). Decreased bcl-2 
protein expression in induced cells was associated with down- 
regulation of its mRNA. By contrast, the decrease in bax 
occurred by a post-transcriptional mechanism. Co-ordinate 
downregulation of bcl-2 and bax proteins may fine-tune the 
induction of apoptosis during cellular differentiation. 
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1. Introduction 
Apoptosis is a form of physiological cell death regulated by 
endogenous cellular proteins including bcl-2, bcl-X and bax 
[1-3]. High bcl-2/bax ratios favour cell survival whereas low 
ratios promote apoptosis [4]. Therefore, regulation of the rel- 
ative levels of bcl-2 and bax may play an important role in 
modulating the susceptibility of cells to apoptosis. 
Bcl-2 levels decline following the induction of differentia- 
tion of HL60 myeloid leukaemia cells [5-7], a process which 
results in eventual apoptosis. Abrogation of differentiation- 
linked cell death by ectopic bcl-2 expression [6,7] suggests 
that the downregulation of this protein is an important deter- 
minant of apoptosis in this system. Because enforced expres- 
sion of bcl-2 increases the stability of the bax protein [8], we 
carried out experiments to determine whether bax levels also 
changed during HL60 cell differentiation. We show here that 
bax protein levels decreased co-ordinately with bcl-2 when 
HL60 cells were induced to differentiate following treatment 
with phorbol myristate acetate (PMA), dimethyl sulphoxide 
(DMSO) or retinoie acid (RA). 
2. Materials and methods 
2.1. Cells and cell culture 
HL60 cells were maintained in RPMI 1640 medium supplemented 
with 10% fetal calf serum and were induced to differentiate by the 
addition of 10 -6 M RA, 1.4% DMSO or 100 nM PMA as described 
[9-11]. A proportion of the TPA-induced cells adhered to the culture 
flask. These cells were detached by incubation with 0.5 g 1-1 trypsin. 
Data for adherent and non-adherent cells in TPA-treated cultures are 
therefore presented in the figures. 
2.2. Detection of DNA strand breaks 
The random oligonucleotide-primed synthesis (ROPS) method was 
used to estimate the induction of endonuclease-mediated strand 
breaks [12]. 
2.3. Antibodies and Western blotting 
Bcl-2 and actin antibodies were from Oncogene Science, NY, USA. 
The P-19 bax antibody was from Santa Cruz Biotechnology, CA, 
USA. Western blotting was carried out essentially as described [13]. 
Thirty micrograms of protein were loaded in each lane of a 15% SDS- 
polyacrylamide gel. Following electrophoretic transfer to ECL Hy- 
bond (Amersham International, UK), the membrane was incubated 
sequentially with bcl-2, bax or actin monoclonal ntibodies. The blots 
were detected by enhanced chemiluminescence (ECL System, Amer- 
sham International, UK). The bcl-2, bax and actin antibodies detected 
26, 21 and 44 kDa proteins respectively. 
2.4. RNA extraction and cDNA synthesis 
RNA was extracted using the guanidium isothiocyanate/acid phenol 
procedure [14]. Complementary DNA (cDNA) was synthesised from 
1 ~tg aliquots of each RNA preparation using random hexamer prim- 
ers (Boehringer, UK) and Moloney murine leukaemia virus reverse 
transcriptase (Life Technologies, UK). 
2.5. RT PCR and Southern blotting 
PCR was performed in 25 ~tl reactions using Taq DNA polymerase 
(Life Technologies, UK). cDNA equivalent to 0.1 ~g RNA was am- 
plified in each reaction. Forward (F) and reverse (R) primers for 
quantitation of mRNA, designed to span at least one intron, were 
as follows: Actin F: TGC TAT CCA GGC TGT GCT AT (nts 443- 
462). Actin R: GAT GGA GTT GAA GGT AGT TT (nts 887-868 
[15]). Bcl-2 F: ACA ACA TCG CCC TGT GGA TGA C (nts 512- 
533). Bcl-2 R: ATA GCT GAT TCG ACG TTT TGC C (nts 920- 
899; Fig. 3A of [16]). Bax F: TGA CGG CAA CTT AAC TGG G 
(nts 303--322). Bax R: TTC CAG ATG GTG AGC GAG G (nts 569- 
548 [3]). Primary (unspliced) bcl-2 transcripts were quantitated using 
the bcl-2 F primer in conjunction with a reverse primer located within 
the second intron of the bcl-2 gene (AGC CCA GAC TCA CAT CAC 
CAG ATG; nucleotides 616-593; Fig. 3B of [16]). PCR annealing 
temperatures of 54°C, 56°C and 59°C were used for amplification 
using actin, bcl-2 and bax primers respectively. 
PCR products were electrophoresed in 2% w/v agarose gels, trans- 
ferred to Hybond N membranes (Amersham International, UK) and 
hybridised to a2p-labelled riboprobes generated by in vitro transcrip- 
tion of sequences cloned into the bluescript vector (Stratagene, Cam- 
bridge, UK). Autoradiographic bands were quantitated using a Mo- 
lecular Dynamics Scanner. The cDNA inputs and cycle numbers used 
for PCR analysis were established in preliminary experiments such 
that the product band intensity was proportional to the cDNA input. 
Each PCR reaction was sampled following 20, 22, 24 and 26 cycles to 
ensure that reactions were in the exponential phase of amplification. 
For clarity, the bands resulting from 22 amplification cycles only have 
been excised for presentation (Fig, 4). 
3. Results 
*Corresponding author. Fax: (44) (171) 431-4537. Treatment of HL60 cells with PMA induces their differen- 
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Fig. 1. Detection of DNA cleavage in HL60 cells treated with 100 nM PMA (A) or 10 6 M RA (B). The incorporation of cc-[~2P]dCTP is pro- 
portional to DNA strand breaks [12]. The bars indicate the range of duplicate measurements. 
tiation to cells resembling macrophages, a proportion of 
which adhere to the culture flask [11]. By contrast, DMSO 
and RA induce differentiation to cells resembling ranulocytes 
[9,10]. Both these pathways result in eventual apoptosis 
[6,7,17]. We have confirmed that PMA (Fig. 1A) or RA 
(Fig. 1B) treatment induces DNA strand breakage, an early 
feature of apoptosis [12], in HL60 cells. In PMA-treated cells, 
induction of strand breaks was only detected in the non-ad- 
herent population, as previously reported [17]. We have also 
confirmed the induction of DNA strand breaks in DMSO- 
treated cells using the TUNEL assay [18] (data not shown). 
Western blot analysis showed that the bcl-2 protein was 
downregulated in HL60 cells treated with PMA (Fig. 2A,), 
DMSO (Fig. 2B) or RA (Fig. 2C). In PMA-treated cultures 
bcl-2 downregulation was clearly evident in both the adherent 
and non-adherent cell populations (Fig. 2A). The downregu- 
lation of bcl-2 protein during HL60 differentiation was con- 
firmed by densitometric s anning of the bands and their nor- 
malisation with respect o actin band intensities determined 
on the same blots (Fig. 3A,C,E). Bax protein expression was 
also strikingly downregulated following induction of differen- 
tiation by each of the agents tested (Fig. 2). Quantitation of 
the bax bands and normalisation with respect to actin showed 
that the time-courses of bax downregulation i HL60 cells 
induced to differentiate by each of the three agents tested 
were similar to that of the decline of bcl-2 expression (Fig. 
3B,D,F). 
To determine whether downregulation of bcl-2 and bax 
protein were mediated via modulation of their respective 
mRNAs, we analysed the expression of the transcripts encod- 
ing these species by semi-quantitative RT PCR procedures. 
The bcl-2 or bax bands generated by RT PCR were detected 
by Southern blotting using appropriate radiolabelled probes 
and were normalised with respect o actin RT PCR bands 
generated by amplification of the same cDNAs. Bcl-2 
mRNA expression declined sharply in both adherent and 
non-adherent cells following PMA treatment (Fig. 4A, Fig. 
5A) and in cultures induced with DMSO (Fig. 4B, Fig. 5C) 
or with RA (Fig. 4C, Fig. 5E). These observations suggest 
that the decline in bcl-2 protein results from a decrease in 
cellular levels of bcl-2 mRNA following the induction of dif- 
ferentiation by each of the agents tested and are compatible 
with a transcriptional mechanism of downregulation of bcl-2 
expression. 
The bcl-2 gene contains a large (> 350 kb) intron. Because 
RA treatment modulates the splicing of some primary tran- 
scripts [19], we determined whether the decline in bcl-2 
mRNA levels in RA-treated HL60 cells resulted from a de- 
creased rate of excision of this intron from primary tran- 
scripts. Simultaneous RT PCR analyses were performed using 
primer pairs which amplified either the spliced or the un- 
spliced bcl-2 transcript (Section 2.5). Both types of transcript 
declined in parallel following RA treatment (Fig. 6), showing 
that the RA-induced downregulation of bcl-2 mRNA was not 
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Fig. 2. Western blot analysis for actin, bcl-2 and bax proteins in HL60 cells treated with 100 nM PMA (A), 1.4% DMSO (B) or 10 -6 M RA 
(C). The days after addition of inducers are indicated above the lanes. In (A), N and A denote non-adherent and adherent cells respectively. In
(B), C and D denote control and DMSO-treated cells. In (C), C and RA denote control and RA-treated cells. 
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Fig. 3. Quantitation of expression of bcl-2 and bax proteins in HL60 cells treated with PMA (A,B), DMSO (C,D) or RA (E,F). The protein 
bands depicted in Fig. 2 were scanned. The intensities of bcl-2 and bax bands were normalised with respect o the intensities of actin bands de- 
tected on the same blots. Similar results were obtained in two independent experiments. 
A. B. C. 
DO D1 D2 D4 DO D1 D3 D6 DO D1 D3 
N N A N A N A C C D C D C D C C RA C RA 
Fig. 4. RT PCR analysis for actin, bcl-2 and bax mRNA in HL60 cells treated with 100 nM PMA (A), 1.4% DMSO (B) or 10 -6 M RA (C). 
Labelling of lanes is as in Fig. 2. 
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Fig. 5. Quantitation of expression of bcl-2 and bax mRNA in HL60 cells treated with PMA (A,B), DMSO (C,D) or RA (E,F). The RT PCR 
product bands depicted in Fig. 4 were scanned. The intensities of bcl-2 and bax bands in each cDNA sample were normalised with respect to 
the intensities of actin bands detected by PCR amplification of the same cDNA. Similar results were obtained in three independent experi- 
ments. 
the result of impaired splicing. Instead, the data are compat- 
ible with the RA-induced downregulation of generation of 
primary bcl-2 transcripts. 
By contrast, bax protein expression (Fig. 3B) declined be- 
fore substantial downregulation of bax mRNA levels were 
detected in either adherent or non-adherent PMA-treated 
HL60 cells (Fig. 4A, Fig. 5B). Bax mRNA also remained 
elevated in cells induced to differentiate by treatment with 
either DMSO (Fig. 5D) or with RA (Fig. 5F). These observa- 
tions show clearly that downregulation f bax protein expres- 
sion in differentiating HL60 cells (Fig. 3B,D,F) is mediated by 
a post-transcriptional mechanism. 
4. Discussion 
The downregulation f the anti-apoptotic b l-2 protein dur- 
ing myeloid differentiation is well established [5-7]. Here we 
show for the first time that expression of the pro-apoptotic 
bax protein also declined when HL60 cells were induced to 
differentiate following treatment with three different agents. 
The decrease in bcl-2 and bax expression occurred in the 
same time-flame as did the generation of DNA strand breaks, 
an early event in the commitment of cells to apoptosis [12]. 
Circumstantial evidence suggests that the decrease in bcl-2 
expression during HL60 differentiation may play an impor- 
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Fig. 6. Quantitation of spliced bcl-2 mRNA and unspliced bcl-2 
transcripts in RA-treated HL60 cells. Spliced and unspliced tran- 
scripts were quantitated by RT PCR using the primer pairs de- 
scribed (Section 2.5). Densities of Southern-blotted PCR bands were 
normalised with respect to actin RT PCR bands determined using 
the same samples. 
tant role in triggering the eventual death of differentiating 
HL60 cells [6,7]. Because the susceptibility of cells to apopto- 
sis is determined in part by the ratio of bcl-2 to bax protein, 
the data here are compatible with the hypothesis that the 
downregulation of bax which accompanies the decline in 
bcl-2 expression may play a role in fine-tuning the induction 
of cell death during myeloid differentiation. 
In PMA-treated HL60 cells, the downregulation of bcl-2 
and bax proteins was evident in both the adherent and non- 
adherent populations. DNA strand breakage, however, was 
only detected in the non-adherent cells. A possible explana- 
tion for this apparent discrepancy is that adherent cells which 
become committed to cell death detach from the culture flask 
at an early stage of apoptosis which precedes the appearance 
of DNA scissions. 
Comparison of changes in bcl-2 mRNA and protein levels 
during HL60 cell differentiation suggest hat the fall in bcl-2 
protein expression was modulated via a decrease in bcl-2 
mRNA. In RA-induced cells, the decrease in bcl-2 mRNA 
apparently resulted from diminished levels of the primary 
transcript, consistent with transcriptional downregulation. 
By striking contrast, bax protein levels in differentiating 
HL60 cells declined before a substantial decrease in bax 
mRNA was detectable, strongly suggesting that bax expres- 
sion decreased via a post-transcriptional control mechanism. 
Because bcl-2 protein stabilises bax protein [8], our observa- 
tions are consistent with a model whereby the differentiation- 
linked decrease in bcl-2 results in a de-stabilisation f bax and 
a consequent decline in steady-state bax levels. 
In summary, the data here are compatible with, but do not 
prove, the hypothesis that co-ordinate downregulation f bcl- 
2 and bax proteins play a role in the subtle regulation of the 
onset of apoptosis during the granulocytic and macrophage- 
like differentiation f HL60 cells. However, several additional 
bcl-2-related [2,20,21] and bcl-2-unrelated [22] proteins have 
recently been implicated in the regulation of apoptosis. Com- 
plete characterisation f the control of apoptosis during mye- 
loid cell differentiation will require further studies on the reg- 
ulation of these novel regulators of cell death. 
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